Opinion|Videos|November 25, 2024
VMS Symptoms and Neurokinin Receptor Antagonists
Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.
Advertisement
Episodes in this series
- What are neurokinin 3 (NK3) receptors, and how can antagonism of NK3 receptors affect VMS?
- What is fezolinetant?
Note: The binding affinity of fezolinetant at NK3 receptors is 450 times greater than those for neurokinin 1 (NK1); this is an NK3 and has no NK1 action
- What is elinzanetant?
Note: Elinzanetant is currently under review with the FDA
- How can blockade of NK1 and NK3 receptors improve VMS and sleep disturbances associated with menopause?
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG clinical update recommends salpingectomy at time of hysterectomy
2
Report: Postpartum depression market expected to grow based on awareness, pipeline progress
3
Carrie Carda, MD, on peptide therapy for PMOS, endometriosis, and fertility
4
Alexis Totaro, MSN, on assessing distress and executing a warm handoff in postpartum care
5